Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming
Open accessPublished version of a preprint
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Obsessive compulsive disorder (OCD) is a highly prevalent disorder that causes serious disability. Available treatments leave 40% or more of people with OCD significantly symptomatic. There is an urgent need for novel therapeutic approaches. Mice that carry a homozygous deletion of the SAPAP3 gene (SAPAP3 KO) manifest a phenotype of excessive self-grooming, tic-like head-body twitches and anxiety. These behaviors closely resemble pathological self-grooming behaviors observed in humans in conditions that overlap with OCD. Following a preliminary report that the tryptaminergic psychedelic, psilocybin, may reduce symptoms in patients with OCD, we undertook a randomized controlled trial of psilocybin in 50 SAPAP3 KO mice (28 male, 22 female). Mice that fulfilled inclusion criteria were randomly assigned to a single intraperitoneal injection of psilocybin (4.4 mg/kg), psychedelic mushroom extract (encompassing the same psilocybin dose) or vehicle control and were evaluated after 2, 12, and 21 days by a rater blind to treatment allocation for grooming characteristics, head-body twitches, anxiety, and other behavioral features. Mice treated with vehicle (n = 18) manifested a 118.71 ± 95.96% increase in total self-grooming (the primary outcome measure) over the 21-day observation period. In contrast, total self-grooming decreased by 14.60 ± 17.90% in mice treated with psilocybin (n = 16) and by 19.20 ± 20.05% in mice treated with psychedelic mushroom extract (n = 16) (p = 0.001 for effect of time; p = 0.0001 for time × treatment interaction). Five mice were dropped from the vehicle group because they developed skin lesions; 4 from the psilocybin group and none from the psychedelic mushroom extract group. Secondary outcome measures such as head-body twitches and anxiety all showed a significant improvement over 21 days. Notably, in mice that responded to psilocybin (n = 12) and psychedelic mushroom extract (n = 13), the beneficial effect of a single treatment persisted up to 7 weeks. Mice initially treated with vehicle and non-responsive, showed a clear and lasting therapeutic response when treated with a single dose of psilocybin or psychedelic mushroom extract and followed for a further 3 weeks. While equivalent to psilocybin in overall effect on self-grooming, psychedelic mushroom extract showed superior effects in alleviating head-body twitches and anxiety. These findings strongly justify clinical trials of psilocybin in the treatment of OCD and further studies aimed at elucidating mechanisms that underlie the long-term effects to alleviate excessive self-grooming observed in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication
Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.94 · Cited by 2,771 · cited 1×
“Obsessive-compulsive disorder (OCD) affects 2 – 3% of the US population and is characterized by intrusive thoughts (obsessions) and repetitive actions (compulsions) [1, 2].”
Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice
Welch, J. M., Lu, J., Rodriguiz, R. M., Trotta, N. C., Peca, J., Ding, J.-D., Feliciano, C., Chen, M., Adams, J. P., Luo, J., et al. (2007) · Nature · doi:10.1038/nature06104 · Cited by 852
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Kim, E., Naisbitt, S., Hsueh, Y.-P., Rao, A., Rothschild, A., Craig, A. M., & Sheng, M. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.136.3.669 · Cited by 516
MEMBRANE-ASSOCIATED GUANYLATE KINASES REGULATE ADHESION AND PLASTICITY AT CELL JUNCTIONS
Funke, L., Dakoji, S., & Bredt, D. S. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133339 · Cited by 469
Postsynaptic organisation and regulation of excitatory synapses
Scannevin, R. H., & Huganir, R. L. (2000) · Nature Reviews Neuroscience · doi:10.1038/35039075 · Cited by 460
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Takeuchi, M., Hata, Y., Hirao, K., Toyoda, A., Irie, M., & Takai, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.11943 · Cited by 359
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder
Goodman, W. K., Storch, E. A., & Sheth, S. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111601 · Cited by 250
Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study
Bienvenu, O. J., Wang, Y., Shugart, Y. Y., Welch, J. M., Grados, M. A., Fyer, A. J., Rauch, S. L., McCracken, J. T., Rasmussen, S. A., Murphy, D. L., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30897 · Cited by 207 · cited 1×
“Supporting a possible relationship between SAPAP3 and OCD in humans, there is evidence that polymorphisms in the SAPAP3 gene are associated with susceptibility to grooming disorders such as trichotillomania, pathological nail biting and skin picking in [33].”
Multiple rare SAPAP3 missense variants in trichotillomania and OCD
Züchner, S., Wendland, J. R., Ashley-Koch, A. E., Collins, A. L., Tran-Viet, K. N., Quinn, K., Timpano, K. C., Cuccaro, M. L., Pericak-Vance, M. A., Steffens, D. C., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.83 · Cited by 196
de Brouwer, G., Fick, A., Harvey, B. H., & Wolmarans, D. W. (2019) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/s13415-018-00653-4 · Cited by 179
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch, M. H., Wasylink, S., Landeros-Weisenberger, A., Panza, K. E., Billingslea, E., Leckman, J. F., Krystal, J. H., Bhagwagar, Z., Sanacora, G., & Pittenger, C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.028 · Cited by 162
Dunlop, K., Woodside, B., Olmsted, M., Colton, P., Giacobbe, P., & Downar, J. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.292 · Cited by 147 · cited 1×
“…that the disorder is associated with dysfunction of fronto-striatal circuits that play a role in cognitive fl exibility and emotional regulation [37, 15] suggested that increased activity of dorsomedial prefrontal neurons projecting to the dorsomedial striatum may be implicated in the effect of…”
Repetitive Behaviours in Patients with Gilles de la Tourette Syndrome: Tics, Compulsions, or Both?
Worbe, Y., Mallet, L., Golmard, J.-L., Béhar, C., Durif, F., Jalenques, I., Damier, P., Derkinderen, P., Pollak, P., Anheim, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012959 · Cited by 127
Sapap3 Deletion Causes mGluR5-Dependent Silencing of AMPAR Synapses
Wan, Y., Feng, G., & Calakos, N. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2533-11.2011 · Cited by 101
Relief of obsessive-compulsive symptoms by LSD and psilocin
Leonard, H. L., & RAPOPORT, J. L. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.9.1239b · Cited by 81
Schneier, F. R., Feusner, J., Wheaton, M. G., Gomez, G. J., Cornejo, G., Naraindas, A. M., & Hellerstein, D. J. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.031 · Cited by 81
Book Review: Diagnostic and Statistical Manual of Mental Disorders: Fifth Edition (DSM-5)
Kocsis, R. N. (2013) · International Journal of Offender Therapy and Comparative Criminology · doi:10.1177/0306624x13511040 · Cited by 80 · cited 1×
“Grooming disorders such as trichotillomania, hair pulling, and skin picking that occur in humans, are closely related to OCD and are classi fi ed under obsessive-compulsive and related disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [32].”
Manning, E. E., Dombrovski, A. Y., Torregrossa, M. M., & Ahmari, S. E. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0307-2 · Cited by 79 · cited 1×
“It has also been reported that SAPAP3 KO mice manifest increased anxiety [5], impaired cognitive fl exibility [11], and aberrant habit formation [12].”
Effects ofPsilocybe argentipeson Marble-Burying Behavior in Mice
Matsushima, Y., Shirota, O., Kikura‐Hanajiri, R., Goda, Y., & Eguchi, F. (2009) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.90095 · Cited by 73
Shahar, O., Botvinnik, A., Esh-Zuntz, N., Brownstien, M., Wolf, R., Lotan, A., Wolf, G., Lerer, B., & Lifschytz, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214148 · Cited by 65
Self-citationGlutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62
Automated classification of self-grooming in mice using open-source software
van den Boom, B. J. G., Pavlidi, P., Wolf, C. J. H., Mooij, A. H., & Willuhn, I. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.05.026 · Cited by 62
Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113093 · Cited by 62
Singh, S., Botvinnik, A., Shahar, O., Wolf, G., Yakobi, C., Saban, M., Salama, A., Lotan, A., Lerer, B., & Lifschytz, T. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02456-9 · Cited by 59
Self-citationLifschytz, T., Broner, E. C., Zozulinsky, P., Slonimsky, A., Eitan, R., Greenbaum, L., & Lerer, B. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001453 · Cited by 57
Self-citationAberrant habit formation in the Sapap3-knockout mouse model of obsessive-compulsive disorder
Hadjas, L. C., Lüscher, C., & Simmler, L. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-48637-9 · Cited by 56
Lamothe, H., Schreiweis, C., Mondragón-González, S. L., Rebbah, S., Lavielle, O., Mallet, L., & Burguière, E. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02323-7 · Cited by 52
Shahar, O., Botvinnik, A., Shwartz, A., Lerer, E., Golding, P., Buko, A., Hamid, E., Kahn, D., Guralnick, M., Blakolmer, K., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02477-w · Cited by 40
Self-citationLugo-Radillo, A., & Cortés-López, J. L. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1849879 · Cited by 39
Davis, G. L., Minerva, A. R., Lario, A., Simmler, L. D., Rodríguez, C. I., & Gunaydin, L. A. (2021) · Nature Communications · doi:10.1038/s41467-021-26247-2 · Cited by 37
Lotan, A., Lifschytz, T., Slonimsky, A., Broner, E. C., Greenbaum, L., Abedat, S., Fellig, Y., Cohen, H. R., Lory, O., Goelman, G., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.123 · Cited by 32
Self-citationBehavioral fragmentation in the D1 CT ‐7 mouse model of Tourette's syndrome
Santangelo, A., Bortolato, M., Mosher, L. J., Crescimanno, G., Giovanni, G. D., Cassioli, E., Ricca, V., & Casarrubea, M. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12789 · Cited by 30
Rizzo, F. R., Nespoli, E., Abaei, A., Bar‐Gad, I., Deelchand, D. K., Fegert, J. M., Rasche, V., Hengerer, B., & Boeckers, T. M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00059 · Cited by 21
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders
Heresco‐Levy, U., & Lerer, B. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02312-8 · Cited by 15
Self-citation
Cited by
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles
Rogers, S. A., Heller, E. A., & Corder, G. F. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01964-9 · Cited by 30
Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110202 · Cited by 17
The Emergence of Psilocybin in Psychiatry and Neuroscience
Omidian, H., & Omidian, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040555 · Cited by 16
Gattuso, J. J., Kong, G., Bezcioglu, B., Lu, D., Ekwudo, M. N., Wilson, C., Gubert, C., Hannan, A. J., & Renoir, T. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110648 · Cited by 11
Payamani, M., Abdollahi-Keyvani, S.-T., Sajjadi, M., Akhondzadeh, S., Javid, R., Nakhaei-Zadeh, R., Jalalian-Javadpour, M., & Vaseghi, S. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174027 · Cited by 8
Metadata
- Authors
- Brownstien, M., Lazar, M., Botvinnik, A., Shevakh, C., Blakolmer, K., Lerer, L., Lifschytz, T., & Lerer, B.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Corresponding author
- Lifschytz, Tzuri
- Lerer, Bernard
- Venue
- Molecular Psychiatry
- Published
- 2024-10-11
- Volume
- 30
- Issue
- 3
- Pages
- 1172-1183
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC11835722
- OpenAlex
- W4403328142
- Cited by
- 30
- References
- 39
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 1
- FWCI
- 15.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- Parow Emtheobiosciences (ParowBio) Back of the yards algae sciences
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psilocybin, obsessive-compulsive disorder, anxiety, long-term treatment outcomes, animal model of OCD, treatment-resistant OCD
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.